Alnylam Pharmaceuticals, Inc.
ALNY
$332.92
$1.680.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 212.79% | 113.11% | -337.46% | 18.78% | 36.82% |
| Total Depreciation and Amortization | -1.79% | 139.68% | 70.96% | 38.72% | 4.84% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.30% | 54.59% | 0.24% | 10.11% | -1.34% |
| Change in Net Operating Assets | -107.76% | -814.23% | -244.53% | -1,023.50% | -473.87% |
| Cash from Operations | 6,405.10% | 370.10% | -104.17% | -123.85% | -107.98% |
| Capital Expenditure | -71.24% | -9.90% | 31.55% | 50.61% | 44.90% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 699.57% | 276.11% | 67.97% | 135.59% | 69.88% |
| Cash from Investing | 473.44% | 238.08% | 61.15% | 119.69% | 65.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -17.47% | -17.80% | 28.26% | 149.30% | 105.44% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 5.91% | -1,553.51% | -334.90% | -172.20% | -135.64% |
| Cash from Financing | -203.75% | -205.66% | -0.51% | 99.99% | 70.89% |
| Foreign Exchange rate Adjustments | 329.25% | 80.73% | 551.88% | 252.99% | -338.44% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 348.83% | 480.05% | -53.52% | 3,174.45% | 386.50% |